Risk factors for long-term vision loss after trabeculectomy included preoperative split fixation on visual fields
Risk factors for long-term vision loss after trabeculectomy included preoperative split fixation on visual fields, according to a study published in the Archives of Ophthalmology.
The study led by Dr Brian A. Francis, Department of Ophthalmology, Doheny Eye Institute, Los Angeles, California, USA, investigated the medical records of 301 eyes in 262 patients who underwent trabeculectomy between January 1999 and September 2003. Mild or moderate postoperative vision loss was categorized by a decrease in Snellen acuity of 3 – 5 lines. Permanent postoperative vision loss was identified if visual acuity did not return to 3 lines within the 6-month follow up period.
Of the 301 eyes studied, 24 suffered from permanent vision loss, 13 presented with mild or moderate vision loss and 11 experienced severe vision loss. Permanent mild or moderate vision loss in 10 eyes and permanent severe vision loss 6 eyes had no identifiable cause.
Transient vision loss was experienced in 170 eyes. This consisted of 79 eyes with mild or moderate vision loss and 91 eyes with severe vision loss. The mean recovery times were 88 days and 78 days, respectively.
The risk factors identified in the study included preoperative split fixation on visual fields, preoperative number of quadrants with split fixation, and postoperative choroidal effusions with eventual resolution.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.